These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 6127353)

  • 61. Fluphenazine decanoate. Its steady-state pharmacologic profile and relationship to tardive dyskinesia.
    Glazer WM
    Schizophr Res; 1988; 1(6):425-9. PubMed ID: 3154530
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The prevalence of presumed tardive dyskinesia in psychiatric inpatients and outpatients.
    Kane J; Wegner J; Stenzler S; Ramsey P
    Psychopharmacology (Berl); 1980; 69(3):247-51. PubMed ID: 6106258
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Variation in oro-facial tardive dyskinesia during depot antipsychotic drug treatment.
    Barnes TR; Wiles DH
    Psychopharmacology (Berl); 1983; 81(4):359-62. PubMed ID: 6140703
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Reduced glutamate decarboxylase activity in the subthalamic nucleus in patients with tardive dyskinesia.
    Andersson U; Häggström JE; Levin ED; Bondesson U; Valverius M; Gunne LM
    Mov Disord; 1989; 4(1):37-46. PubMed ID: 2927401
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Tardive dyskinesia and serum iron indices.
    Wirshing DA; Bartzokis G; Pierre JM; Wirshing WC; Sun A; Tishler TA; Marder SR
    Biol Psychiatry; 1998 Sep; 44(6):493-8. PubMed ID: 9777182
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Tardive dyskinesia: preclinical and clinical aspects.
    Gattaz WF; Gerlach J
    Eur Arch Psychiatry Clin Neurosci; 1993; 243(2):116-8. PubMed ID: 8105897
    [No Abstract]   [Full Text] [Related]  

  • 67. Seven-year follow-up of tardive dyskinesia in Hungarian outpatients.
    Gardos G; Perenyi A; Cole JO; Samu I; Kocsis E; Casey DE
    Neuropsychopharmacology; 1988 May; 1(2):169-72. PubMed ID: 2908016
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Prospective study of tardive dyskinesia in the elderly.
    Saltz BL; Kane JM; Woerner MG; Lieberman JA; Alvir JM; Blank K; Kahaner K; Foley C
    Psychopharmacol Bull; 1989; 25(1):52-6. PubMed ID: 2772118
    [No Abstract]   [Full Text] [Related]  

  • 69. Functional analysis of tardive dyskinesia: implications for assessment and treatment.
    Valdovinos MG; Roberts C; Kennedy CH
    J Appl Behav Anal; 2005; 38(2):239-42. PubMed ID: 16033170
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The changing effector pattern of tardive dyskinesia during the course of neuroleptic withdrawal.
    Newell KM; Wszola B; Sprague RL; Mahorney SL; Bodfish JW
    Exp Clin Psychopharmacol; 2001 Aug; 9(3):262-8. PubMed ID: 11534536
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Instrumental assessment of lingual motor instability in tardive dyskinesia.
    Caligiuri MP; Jeste DV; Harris MJ
    Neuropsychopharmacology; 1989 Dec; 2(4):309-12. PubMed ID: 2575388
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Risk factors for orofacial and limbtruncal tardive dyskinesia in older patients: a prospective longitudinal study.
    Paulsen JS; Caligiuri MP; Palmer B; McAdams LA; Jeste DV
    Psychopharmacology (Berl); 1996 Feb; 123(4):307-14. PubMed ID: 8867868
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Voluntary movement dysfunction in Huntington's disease and tardive dyskinesia.
    David AS; Jeste DV; Folstein MF; Folstein SE
    Acta Neurol Scand; 1987 Feb; 75(2):130-9. PubMed ID: 2883804
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Epidemiology of tardive dyskinesia in the elderly.
    Blowers AJ
    Neuropharmacology; 1981 Dec; 20(12B):1339-40. PubMed ID: 6119647
    [No Abstract]   [Full Text] [Related]  

  • 75. Incidence and risk factors for severe tardive dyskinesia in older patients.
    Caligiuri MP; Lacro JP; Rockwell E; McAdams LA; Jeste DV
    Br J Psychiatry; 1997 Aug; 171():148-53. PubMed ID: 9337951
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The preventative role of antioxidants (selegiline and vitamin E) in a rat model of tardive dyskinesia.
    Sachdev P; Saharov T; Cathcart S
    Biol Psychiatry; 1999 Dec; 46(12):1672-81. PubMed ID: 10624549
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Tardive dyskinesia and current dose of neuroleptic drugs.
    Kolakowska T; Williams AO; Ardern M
    Arch Gen Psychiatry; 1986 Jun; 43(6):614. PubMed ID: 2871820
    [No Abstract]   [Full Text] [Related]  

  • 78. Genome-wide association mapping of loci for antipsychotic-induced extrapyramidal symptoms in mice.
    Crowley JJ; Kim Y; Szatkiewicz JP; Pratt AL; Quackenbush CR; Adkins DE; van den Oord E; Bogue MA; Yang H; Wang W; Threadgill DW; de Villena FP; McLeod HL; Sullivan PF
    Mamm Genome; 2012 Jun; 23(5-6):322-35. PubMed ID: 22207321
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Risk factors for tardive dyskinesia in a large population of youths and adults.
    Wszola BA; Newell KM; Sprague RL
    Exp Clin Psychopharmacol; 2001 Aug; 9(3):285-96. PubMed ID: 11534539
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Relationship between the B-mitten EEG pattern and tardive dyskinesia. A pilot control study.
    Wegner JT; Struve FA; Kantor JS; Kane JM
    Arch Gen Psychiatry; 1979 May; 36(5):599-603. PubMed ID: 35118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.